Opiant logo.jpg
Opiant Pharmaceuticals Announces Appointment of Biopharmaceutical Leader Craig A. Collard as Chairman to its Board of Directors
December 07, 2020 16:01 ET | Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
Opiant logo.jpg
Opiant Pharmaceuticals Announces Third Quarter 2020 Financial Results and Corporate Update
November 12, 2020 16:05 ET | Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
Opiant logo.jpg
Opiant Pharmaceuticals to Participate at the Jefferies 2020 Virtual London Healthcare Conference
November 02, 2020 16:01 ET | Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
Opiant logo.jpg
Opiant Pharmaceuticals Partners with Aptar Pharma for Nasal Nalmefene Opioid Overdose Treatment
October 29, 2020 16:05 ET | Opiant Pharmaceuticals, Inc.
Agreement combines Opiant’s opioid antagonist OPNT003 nasal nalmefene, with Aptar's FDA-approved Unit Dose System delivery device Reinforces Opiant’s continued commitment to innovative overdose...
Opiant logo.jpg
Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020
October 27, 2020 16:01 ET | Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
Opiant logo.jpg
Opiant Pharmaceuticals to Participate at the 2020 Cantor Global Virtual Healthcare Conference
August 31, 2020 16:05 ET | Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
Opiant logo.jpg
Opiant Pharmaceuticals Announces Second Quarter 2020 Financial Results and Corporate Update
August 06, 2020 16:05 ET | Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
Opiant logo.jpg
Opiant Pharmaceuticals to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020
July 23, 2020 16:01 ET | Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
Opiant logo.jpg
Opiant Pharmaceuticals Statement on U.S. District Court Decision
June 05, 2020 21:37 ET | Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., June 05, 2020 (GLOBE NEWSWIRE) -- Today, the U.S. District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN® (naloxone HCl)...
Opiant logo.jpg
Opiant Pharmaceuticals to Present at the 2020 Jefferies Virtual Healthcare Conference
May 26, 2020 16:05 ET | Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., May 26, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...